News & Events

Limaca’s Precision-GI™ Granted CMS Transitional Pass-Through (TPT) Payment

Precision-GI™ FDA Designated Breakthrough product and FDA cleared semi-automated motorized endoscopic biopsy device entering U.S. market

7 November 2024

Medtech

The Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for Limaca Medical Ltd. (“Limaca”)’s Precision-GI™ motorized endoscopic biopsy device. Limaca’s endoscopic device is designed to obtain improved biopsy results for patients with suspected gastrointestinal cancers such as pancreatic, liver, and other GI-related and adjacent organs cancers and illnesses. The Precision-GI™ TPT grant is for up to three years beginning January 1, 2025, thus supporting patient access to Limaca’s new and innovative technology; previously, Precision-GI™ was granted the FDA’s Breakthrough Device Designation in 2022 and received clearance by the U.S. Food and Drug Administration (FDA) in August 2023.

The purpose of the TPT program is to support access to newly approved innovative technologies where the costs to adopt them may otherwise inhibit patient access. The TPT program reduces barriers for Medicare beneficiaries to access critical healthcare innovations shortly after products receive FDA approval by providing hospitals with additional payments to cover their costs, while allowing CMS to collect necessary cost data to determine future outpatient payments.

Endoscopic biopsy is a mainstay diagnostic procedure performed with standard manually operated needles threaded through the working channel of the endoscopic ultrasound (EUS) device to visualize and access the target suspect lesion. Due to Precision-GI’s motorized, automated, rotating cutting mechanism, much better quality tissue can be taken, with less blood content, in a single pass, saving critical procedure time and effort. A major benefit for patients over current endoscopic biopsy devices is the ability to consistently obtain superior volume and quality tissue acquisition needed for histopathologic and molecular analysis along with a high quality outcome, and standardization across a broad variation of physician skill levels.

Limaca’s Precision-GI performed its first U.S.-based cases in September 2024 and is now commencing U.S. market entry. A total of 510,992 new cases of pancreatic cancer were recorded around the world in 2022, with some of the highest rates occurring in JapanUSAGermany, UK, and France – all between 8.0 – 9.8 per ASR (age standardized rates)[1]. Precision-GI is additionally working toward Japan’s PMDA clearance and market entry along with its partner HekaBio.

[1] World Cancer Research Fund International
https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/

Receiving TPT approval for our Precision-GI™ product is a major accomplishment for Limaca, enabling greater patient access to the breakthrough device, standardizing higher quality outcomes for these critical endoscopic biopsy procedures, and reducing repeat procedures for patients anxiously awaiting diagnostic results for suspected pancreatic and other GI cancers. Very few products are granted TPT, and even fewer achieve both TPT and the FDA’s Breakthrough designation. We are proud of these achievements and deeply pleased that the CMS TPT grant will enable broad patient access to Precision-GI.
Assaf Klein, CEO Limaca Medical

See More News

19 December 2021
Agrifood

FruitSpec raises $5 million

FruitSpec’s Yield Management Platform provides digital visibility of fruit yield data to entire supply-chain production units

16 September 2020
Agrifood

Phytolon secures $4.1 million in funding

Funding for fermentation-based technology for the production of food colors

Skip to content